marginal zone lymphoma epidemiology forecast
DelveInsight’s ‘Marginal Zone Lymphoma—Epidemiology Forecast–2034’ report delivers an in-depth understanding of the MZL, historical and forecasted epidemiology as well as the MZL trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2017–2034
Marginal Zone Lymphoma Disease Understanding
Marginal zone B-cell lymphoma or Marginal Zone Lymphoma (MZL) is a group of indolent (slow-growing) NHL B-cell lymphomas, which account for approximately 5‒17% of all NHL cases. MZL account for about 5–10% of lymphomas and represent approximately 5–15% of all non-Hodgkin lymphomas in the Western world. They tend to be slow-growing (indolent). The cells in these lymphomas look small under the microscope. In the World Health Organization classification, there are three different MZL entities with specific diagnostic criteria, behavior, and therapeutic implications: the extranodal MZL of mucosa-associated lymphoid tissue (MALT) type (MALT lymphoma), the splenic MZL (SMZL), and the nodal MZL (NMZL). Currently, the first-line management of MZL totally depends on supportive therapies, and the two therapies that are approved are for relapsed and refractory MZL patient pool.
Marginal Zone Lymphoma Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total incident cases of Non-Hodgkin lymphoma, Total incident cases of Marginal Zone Lymphoma, Gender-specific incident cases of MZL, Subtype-specific incident cases of MZL, and Stage-specific incident cases of MZL, scenario of MZL in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2034.
Marginal Zone Lymphoma Detailed Epidemiology Segmentation
- As per DelveInsight estimates, the incident cases of NHL in the 7MM was 166,967 cases in 2017.
- The estimates suggest a higher incidence of MZL in the United States with 7,188 cases in 2017.
- The epidemiological model of DelveInsight estimates a higher proportion of MZL cases was found in stage III as compared to other stages in the United States. In 2017, stage I, stage II, and stage III MZL incident cases were 1,416, 465, and 5,307 respectively, in the US.
- MALT lymphoma has the highest incident population with 5,032 cases followed by SMZL with 1,438 cases and NMZL with 719 cases, in 2017, in the US.
- Among the EU5 countries, the UK had the highest incident population of MZL with 3,142 cases, followed by France which had an incident population of 1,748 in 2017. On the other hand, Spain had the lowest incident population of 763 cases in 2017.
Scope of the Report
- The report covers the descriptive overview of MZL, explaining its causes, symptoms, pathophysiology, and genetic basis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of MZL.
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM by Total incident cases of Non-Hodgkin lymphoma, Total incident cases of Marginal Zone Lymphoma, Gender-specific incident cases of MZL, Subtype-specific incident cases of MZL, and Stage-specific incident cases of MZL.
Explore the key factors, trends, innovations, and developments driving the market growth, at: Marginal Zone Lymphoma Market
Report Highlights
- 10-year forecast of MZL
- 7MM Coverage
- Total incident cases of Non-Hodgkin lymphoma
- Total incident cases of Marginal Zone Lymphoma
- Gender-specific incident cases of MZL
- Subtype-specific incident cases of MZL
- Stage-specific incident cases of MZL.
Key Questions Answered
- What are the disease risk, burden, and unmet needs of MZL?
- What is the historical MZL patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of MZL at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to MZL?
- Out of the above-mentioned countries, which country would have the highest prevalent population of MZL during the forecast period (2020–2034)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2034)?
Reasons to buy
The MZL report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM MZL epidemiology forecast.
- The MZL epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The MZL epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
